Q-omics provides the consensus-scored ZNF740 profile across patient tissues and cancer cell-line models. ZNF740 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZNF740 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, ZNF740 protein abundance shows 28,287 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight HNSC as cancer lineages where ZNF740 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF740 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF740 survival associations across molecular data types. ZNF740 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF740 RNA expression–survival associations across cancer types. High ZNF740 expression shows unfavorable associations in ACC, LIHC and KICH, but favorable associations in HNSC, KIRC and GBM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ZNF740 RNA expression.
This table summarizes ZNF740 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF740. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF740 shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, COAD, CHOL and LUSC. The HNSC box plot shows higher ZNF740 RNA expression in tumor versus normal tissue (log2 FC = +0.725, t-test p < 0.001).
This table shows molecular features associated with ZNF740 in patient tissues and cancer cell lines. In patient samples, ZNF740 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF740 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
